Global Cancer Gene Testing Service Market Growth (Status and Outlook) 2023-2029

Global Cancer Gene Testing Service Market Growth (Status and Outlook) 2023-2029

The global Cancer Gene Testing Service market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Cancer Gene Testing Service is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Cancer Gene Testing Service is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Cancer Gene Testing Service is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Cancer Gene Testing Service players cover Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Twist Bioscience and Sophia Genetics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Cancer Gene Testing Service Industry Forecast” looks at past sales and reviews total world Cancer Gene Testing Service sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Gene Testing Service sales for 2023 through 2029. With Cancer Gene Testing Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Gene Testing Service industry.

This Insight Report provides a comprehensive analysis of the global Cancer Gene Testing Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Gene Testing Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Gene Testing Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Gene Testing Service and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Gene Testing Service.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Gene Testing Service market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Breast Cancer Risk Genetic Testing
Stomach Cancer Risk Gene Testing
Rectal Cancer Risk Genetic Testing
Others

Segmentation by application
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Natera, Inc.
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche Ltd
Quest Diagnostics Incorporated
CooperSurgical, Inc.
Agilent Technologies, Inc.
Thermo Fisher Scientific, Inc.
Twist Bioscience
Sophia Genetics
Fulgent Genetic, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.